Advanced stage mucinous epithelial ovarian cancer: The Hellenic Cooperative Oncology Group experience

Gynecologic Oncology

Volumn 97, Issue 2, 2005, Pages 436-441

  Pectasides, Dimitrios ^a   Fountzilas, George ^b   Aravantinos, Gerasimos ^c   Kalofonos, Haralampos P ^d   Efstathiou, Eleni ^e   Salamalekis, Emmanouel ^a   Farmakis, Dimitrios ^a   Skarlos, Dimosthenis ^f   Briasoulis, Evangelos ^g   Economopoulos, Theofanis ^a   Dimopoulos, Meletios A ^e  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c AGII ANARGIRI CANCER HOSPITAL   (Greece)

^d UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^e ALEXANDRA HOSPITAL   (Greece)

^f Henry Dunan Hospital   (Greece)

^g UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

Mucinous epithelial ovarian cancer; Platinum based chemotherapy; Response; Survival

Indexed keywords

ALTRETAMINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANALYTIC METHOD; ARTICLE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; EPITHELIUM CELL; EXPERIENCE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MUCINOUS CARCINOMA; OUTCOMES RESEARCH; OVARY CANCER; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TUMOR GROWTH;

EID: 20944439079     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.12.056     Document Type: Article

References (31)

1. R.T. Greenlee, M.B. Hill-Harmon, and T. Murray Cancer statistics, 2001 CA Cancer J. Clin. 51 2001 15 36
2. H.R. Balvert-Locht, J.W. Coebergh, and W.C. Hop Improved prognosis of ovarian cancer in the Netherlands during the period 1975-1985: a registry-based study Gynecol. Oncol. 42 1991 3 8
3. N. Einhorn, B. Nilsson, and K. Sjovall Factors influencing survival in carcinoma of the ovary. Study from a well-defined Swedish population Cancer 55 1985 2019 2025
4. K.D. Swenerton, T.G. Hislop, and J. Spinelli Ovarian carcinoma: a multivariate analysis of prognostic factors Obstet. Gynecol. 65 1985 264 270
5. M.P. Boente, R. Schilder, and R.F. Ozols Gynecologic cancers Cancer Chemother. Biol. Response Modif. 17 1997 536 561
6. V. McGuire, C.A. Jesser, and A.S. Whittemore Survival among U.S. women with invasive epithelial ovarian cancer Gynecol. Oncol. 84 2002 399 403
7. W.P. McGuire, W.J. Hoskins, and M.F. Brady Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N. Engl. J. Med. 334 1996 1 6
8. M.J. Piccart, K. Bertelsen, and K. James Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results J. Natl. Cancer Inst. 92 2000 699 708
9. F.M. Muggia, P.S. Braly, and M.F. Brady Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study J. Clin. Oncol. 18 2000 106 115
10. J.P. Neijt, S.A. Engelholm, and M.K. Tuxen Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer J. Clin. Oncol. 18 2000 3084 3092
11. International Collaborative Ovarian Neoplasm Group Paclitaxel plus carboplatin versus standard chemotherapy with single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial Lancet 360 2002 505 515
12. V. Hess, R. A'Hern, and N. Nasiri Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment J. Clin. Oncol. 22 2004 1040 1044
13. T. Enomoto, C. Kuragaki, and M. Yamasaki Is clear cell carcinoma and mucinous carcinoma of the ovary sensitive to combination chemotherapy with paclitaxel and carboplatin? Proc.-Am. Soc. Clin. Oncol. 22 2003 44 [abstr 1797]
14. Y. Shimizu, H. Nagata, and Y. Kikuchi Cytotoxic agents active against mucinous adenocarcinoma of the ovary Oncol. Rep. 5 1998 99 101
15. Y. Shimizu, S. Umezawa, and K. Hasumi A phase II study of combined CPT-11 and mitomycin-C in platinum refractory clear cell and mucinous ovarian carcinoma Ann. Acad. Med. Singapore 27 1998 650 656
16. World Health Organization WHO handbook for reporting results of cancer treatment (WHO offset publication no. 48) 1979 World Health Organization Geneva, Switzerland
17. Alan Agresti Categorical data analysis 1990 John Wiley and Sons New York, NY
18. E. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J. Am. Stat. Assoc. 53 1958 457 481
19. D. Cox Regression models and life tables (with discussion) J. R. Stat. Soc., B 34 1972 187 220
20. B.A. Goff, R. Sainz de la Cuesta, and H.G. Muntz Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease Gynecol. Oncol. 60 1996 412 417
21. F. Kikkawa, M. Kawai, and K. Tamakoshi Mucinous carcinoma of the ovary. Clinicopathologic analysis Oncology 53 1996 303 307
22. K. Nomura, and S. Aizawa Noninvasive, microinvasive, and invasive mucinous carcinomas of the ovary: a clinicopathologic analysis of 40 cases Cancer 89 2000 1541 1546
23. W.J. Hoskins, B.N. Bundy, and J.T. Thigpen The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study Gynecol. Oncol. 47 1992 159 166
24. P.A. Andrews, S. Velury, and S.C. Mann cis-Diamminedichloroplatinum (II) accumulation in sensitive and resistant human ovarian carcinoma cells Cancer Res. 48 1988 68 73
25. K. Kasahara, Y. Fujiwara, and K. Nishio Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin Cancer Res. 51 1991 3237 3242
26. J. Kigawa, Y. Minagawa, and X. Cheng Gamma-glutamyl cysteine synthetase up-regulates glutathione and multidrug resistance-associated protein in patients with chemoresistant epithelial ovarian cancer Clin. Cancer Res. 4 1998 1737 1741
27. K.R. Johnson, K.K. Young, and W. Fan Antagonistic interplay between antimitotic and G1-S arresting agents observed in experimental combination therapy Clin. Cancer Res. 5 1999 2559 2565
28. R.T. Gerhardt, J.P. Perras, and B.U. Sevin Characterization of in vitro chemosensitivity of perioperative human ovarian malignancies by adenosine triphosphate chemosensitivity assay Am. J. Obstet. Gynecol. 165 1991 245 255
29. D. Pectasides, M. Pectasides, and D. Farmakis Oxaliplatin plus high dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant, taxane-pretreated: ovarian cancer. A phase II study Gynecol. Oncol. 95 2004 165 172
30. M. Fujita, T. Enomoto, and Y. Murata Genetic alterations in ovarian carcinoma: with specific reference to histological subtypes Mol. Cell. Endocrinol. 202 2003 97 99
31. M. Pieretti, C. Hopenhayn-Rich, and N.H. Khattar Heterogeneity of ovarian cancer: relationships among histological group, stage of disease, tumor markers, patient characteristics, and survival Cancer Invest. 20 2002 11 23